Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pentamycin, also known as fungichromin, is a polyene macrolide antifungal antibiotic derived from Streptomyces pentaticus. It acts primarily by increasing cell membrane permeability in susceptible organisms. Pentamycin exhibits broad-spectrum activity against fungi, protozoa, and some bacteria and is used mainly for the treatment of infectious vaginitis (including vaginal candidiasis and trichomoniasis) as well as mixed infections. It is typically administered locally via vaginal pessaries or tablets and has minimal systemic absorption due to its large molecular size. Pentamycin has also been investigated for use in pulmonary aspergillosis via inhalation. The drug is notable for its efficacy against pathogens resistant to standard treatments and does not adversely affect the normal vaginal flora[1][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pentamycin.